Vor Biopharma (VOR) Financials

$18.66

$-1.46 (-7.26%)

As on 05-Nov-2026 16:17EST

Market cap

$1,164 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

0.1

P/B Ratio

0.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	--	--
Cost of Revenue	0.05	--	3.53	3.49	8.96	4.45
Gross Profit	-0.05	--	-3.53	-3.49	-8.96	-4.45
Operating Expenses	177.39	371.64	121.19	122.54	84.46	69.02
Operating Profit (EBIT)	-177.42	-371.64	-121.19	-126.04	-93.42	-69.02
Other Income	--	--	--	--	1.32	0.12
Profit before Tax	1,353.74	-695.98	-116.91	-117.86	-92.09	-68.90
Provision for Tax	--	--	--	--	-1.32	-0.12
Profit after Tax (Net Income)	1,353.74	-695.98	-116.91	-117.86	-92.09	-68.90
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-92.09	-70.13

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	-137.17	-164.31	96.66	150.72	250.61	216.26
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	597.14	603.27	27.62	43.53	35.64	16.17
Current Liabilities	36.34	25.17	18.61	15.57	13.12	10.15
Total Liabilities	532.66	464.13	142.89	209.83	299.37	242.59

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	5.79	6.02	46.38	69.03	62.42	28.19
Current Assets	490.52	458.11	96.51	140.80	236.95	214.40
Total Assets	986.84	464.13	142.89	209.83	299.37	242.59
Total Debt*	2.81	3.00	31.83	35.66	38.91	18.01
Net Current Assets	--	432.93	77.90	125.23	223.83	204.25

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-142.71	-99.66	-100.29	-85.14	-69.14
Cash Flow from Investing Activities	--	-48.80	96.86	71.01	-94.09	-91.65
Cash from Financing Activities	--	503.81	53.39	2.94	117.14	232.91
Net Cash Inflow / Outflow	--	--	--	--	-62.10	72.12

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	166.81	-70.50	-34.03	-34.72	-39.61	-37.31
Cash EPS ($)	--	-70.21	-33.01	-33.77	-38.53	-36.53
Adjusted Book Value ($)	--	--	28.14	44.40	107.79	117.11
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-14.46	-29.01	-29.54	-36.62	-37.44
Free Cash Flow per Share ($)	--	-14.55	-29.08	-29.86	-40.26	-39.55

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	4,241.46	-74.26	-49.53	-35.16	-45.80
ROE (%)	--	2,057.65	-94.52	-58.74	-39.45	-52.09
ROA (%)	229.08	-229.31	-66.29	-46.29	-33.99	-43.26
EBIT Margin (%)	--	--	--	--	--	--
Net Margin (%)	--	--	--	--	-6,955.74	-57,898.32
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	222.27	-495.29	0.81	-27.98	-33.67	-58.88
Net Profit Growth (%)	155.26	-495.29	0.81	-27.98	-33.67	-58.98
EPS Growth (%)	143.10	-1.07	0.02	0.12	-0.06	0.04
Book Value Growth (%)	99.31	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	0.07	-0.19	-0.03	-0.06	-0.17	-0.31
Price / Book Value	0.66	-0.79	0.04	0.05	0.06	0.10
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-3.09	0.47	0.50	0.82	1.96	2.49
Close Price ($)	19.08	13.08	22.20	45.00	133.00	232.40
High Price ($)	49.64	65.80	62.80	142.80	254.60	1,272.40
Low Price ($)	6.50	2.62	12.60	32.40	69.60	209.60
Market Cap ($ Cr)	1,164.31	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	-0.02	0.33	0.24	0.16	0.08
Short term debt to equity ratio	0.00	0.00	0.04	0.03	0.01	0.01
Current Ratio	13.50	18.20	5.19	9.04	18.06	21.12
Quick Ratio	13.50	--	--	--	--	--
Interest Coverage	--	--	--	--	-69.56	-44.37

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	--	--	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	--	120.09	135.30	67.61	160.26
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.